BENSALEM, Pa. -- (Business Wire)
Law Offices of Howard G. Smith continues its investigation on behalf of
Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”) (NYSE: TEVA)
investors concerning the Company and its officers’ possible violations
of federal securities laws.
On August 2, 2016, Teva finalized its acquisition of Allergan plc’s
generics business, Actavis Generis. Thereafter, Teva continued to make
positive statements concerning the integration of the business, growth
on intangible assets and goodwill, and general benefits of the
acquisition. However, on August 3, 2017, Teva lowered its outlook and
recorded a $6.1 billion impairment charge.
On this news, the Company’s share price plummeted, falling 45% over six
trading days, to close at $17.19 per share on August 10, 2017, thereby
injuring investors.
If you purchased Teva securities, have information or would like to
learn more about these claims, or have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Howard G. Smith, Esquire, of Law Offices of Howard G.
Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by
telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com,
or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170919006100/en/
Contacts:
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
Source: Law Offices of Howard G. Smith
© 2024 Canjex Publishing Ltd. All rights reserved.